Search Results - "SIEBER, Markus"

Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial by ENGERT, Andreas, FRANKLIN, Jeremy, FRANKE, Astrid, KOCH, Peter, DE WIT, Maike, PAULUS, Ursula, HASENCLEVER, Dirk, LOEFFLER, Markus, MÜLLER, Rolf-Peter, MULLER-HERMELINK, Hans Konrad, DÜHMKE, Eckhart, DIEHL, Volker, THEODOR EICH, Hans, BRILLANT, Corinne, SEHLEN, Susanne, CARTONI, Claudio, HERRMANN, Richard, PFREUNDSCHUH, Michael, SIEBER, Markus, TESCH, Hans

“…To investigate whether combined-modality treatment (CMT) with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by…”
Get full text

Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group by ENGERT, Andreas, SCHILLER, Petra, WILLICH, Normann, MÜLLER, Rolf-Peter, SCHMIDT, Bernhard F, RENNER, Helmut, MÜLLER-HERMELINK, Hans Konrad, PFISTNER, Beate, WOLF, Jürgen, HASENCLEVER, Dirk, LÖFFLER, Markus, DIEHL, Volker, JOSTING, Andreas, HERRMANN, Richard, KOCH, Peter, SIEBER, Markus, BOISSEVAIN, Friederike, DE WIT, Maike, MEZGER, Jörg, DÜHMKE, Eckhart

“…To investigate whether radiotherapy can be reduced without loss of efficacy from extended field (EF) to involved field (IF) after four cycles of chemotherapy…”
Get full text

Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group by JOSTING, Andreas, WIEDENMANN, Sabine, FRANKLIN, Jeremy, MAY, Michael, SIEBER, Markus, WOLF, Juergen, ENGERT, Andreas, DIEHL, Volker

“…To assess the incidence and outcome of secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients with Hodgkin's disease (HD)…”
Get full text

Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group by JOSTING, Andreas, NOGOVA, Lucia, DIEHL, Volker, ENGERT, Andreas, FRANKLIN, Jeremy, GLOSSMANN, Jan-Peter, EICH, Hans Theodor, SIEBER, Markus, SCHOBER, Thomas, BOETTCHER, Heinz-Dietrich, SCHULZ, Ulrich, MÜLLER, Rolf-Peter

“…To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated with salvage radiotherapy…”
Get full text

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial by Giessen, Clemens, von Weikersthal, Ludwig Fischer, Hinke, Axel, Stintzing, Sebastian, Kullmann, Frank, Vehling-Kaiser, Ursula, Mayerle, Julia, Bangerter, Markus, Denzlinger, Claudio, Sieber, Markus, Teschendorf, Christian, Freiberg-Richter, Jens, Schulz, Christoph, Modest, Dominik Paul, Moosmann, Nicolas, Aubele, Philipp, Heinemann, Volker

“…Several randomized trials have indicated that combination chemotherapy applied in metastatic colorectal cancer (mCRC) does not significantly improve overall…”
Get full text

Non-Hodgkin’s Lymphoma After Primary Hodgkin’s Disease in the German Hodgkin’s Lymphoma Study Group: Incidence, Treatment, and Prognosis by RUEFFER, Ulrich, JOSTING, Andreas, FRANKLIN, Jeremy, MAY, Michael, SIEBER, Markus, BREUER, Kai, ENGERT, Andreas, HODGKIN, Volker Diehl For The, GROUP, S. Lymphoma

“…The cumulative incidence for non-Hodgkin lymphoma's (NHL) after primary Hodgkin's disease (HD) ranges between 1% and 6%. To investigate the course of disease…”
Get full text

Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin’s Lymphoma: Final Results of the German Hodgkin’s Lymphoma Study Group Trial HD5 by Sieber, M.

Get full text

Driver perception and reaction in collision avoidance: Implications for ADAS development and testing by Sieber, Markus, Farber, Berthold

“…The quality of an advanced driver assistance system (ADAS) is limited by the quality of its interaction with the driver. For an efficient…”
Get full text

Progress of plated metallization for industrial bifacial TOPCon silicon solar cells by Grübel, Benjamin, Cimiotti, Gisela, Schmiga, Christian, Schellinger, Stefan, Steinhauser, Bernd, Brand, Andreas A., Kamp, Mathias, Sieber, Markus, Brunner, Damian, Fox, Stephen, Kluska, Sven

“…Industrial tunnel oxide and passivated contact (i‐TOPCon) solar cells were metallized at Fraunhofer ISE using ultrashort pulse laser ablation of the…”
Get full text

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial by Schmitz, Norbert, Pfistner, Beate, Sextro, Michael, Sieber, Markus, Carella, Angelo M, Haenel, Matthias, Boissevain, Friederike, Zschaber, Reinhart, Müller, Peter, Kirchner, Hartmut, Lohri, Andreas, Decker, Susanne, Koch, Bettina, Hasenclever, Dirk, Goldstone, Anthony H, Diehl, Volker

“…High-dose chemotherapy followed by transplantation of autologous haemopoietic stem cells (BEAMHSCT) is frequently used to treat patients with relapsed…”
Get full text

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group by Josting, Andreas, Rueffer, Ulrich, Franklin, Jeremy, Sieber, Markus, Diehl, Volker, Engert, Andreas

“…To determine prognostic factors and treatment outcome, patients with primary progressive Hodgkin lymphoma (HD) registered in the database of the German Hodgkin…”
Get full text

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group by Josting, Andreas, Rueffer, Ulrich, Franklin, Jeremy, Sieber, Markus, Diehl, Volker, Engert, Andreas

“…To determine prognostic factors and treatment outcome, patients with primary progressive Hodgkin lymphoma (HD) registered in the database of the German Hodgkin…”
Get full text

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group by Rehwald, Ute, Schulz, Holger, Reiser, Marcel, Sieber, Markus, Staak, Jan Oliver, Morschhauser, Franck, Driessen, Christoph, Rüdiger, Thomas, Müller-Hermelink, Konrad, Diehl, Volker, Engert, Andreas

“…This phase 2 trial was performed to evaluate the safety and efficacy of the chimeric monoclonal anti-CD20 antibody rituximab in patients with relapsed…”
Get full text

Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial by Giessen, Clemens Albrecht, Modest, Dominik Paul, Stintzing, Sebastian, Fischer von Weikersthal, Ludwig, Vehling-Kaiser, Ursula, Spaeth-Schwalbe, Ernst, Freiberg-Richter, Jens, Mayerle, Julia, Bangerter, Markus, Denzlinger, Claudio, Sieber, Markus, Teschendorf, Christian, Peuser, Bettina, Heinemann, Volker

“…Abstract only TPS3639 Background: Several randomized trials have indicated that combination chemotherapy applied in metastatic colorectal cancer (mCRC) does…”
Get full text

A randomized, phase III trial of capecitabine plus bevacizumab in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial by Giessen, Clemens, von Weikersthal, Ludwig Fischer, Hinke, Axel, Stintzing, Sebastian, Kullmann, Frank, Vehling-Kaiser, Ursula, Mayerle, Julia, Bangerter, Markus, Denzlinger, Claudio, Sieber, Markus, Teschendorf, Christian, Freiberg-Richter, Jens, Schulz, Christoph, Modest, Dominik Paul, Moosmann, Nicolas, Aubele, Philipp, Heinemann, Volker

“…Background Several randomized trials have indicated that combination chemotherapy applied in metastatic colorectal cancer (mCRC) does not significantly improve…”
Get full text

A randomized, phase III trial of capecitabine plus bevacizumab by Stintzing, Sebastian, Moosmann, Nicolas, Schulz, Christoph, Bangerter, Markus, von Weikersthal, Ludwig Fischer, Sieber, Markus, Denzlinger, Claudio, Kullmann, Frank, Aubele, Philipp, Heinemann, Volker, Vehling-Kaiser, Ursula, Mayerle, Julia, Modest, Dominik Paul, Giessen, Clemens, Teschendorf, Christian, Freiberg-Richter, Jens, Hinke, Axel

“…Background Several randomized trials have indicated that combination chemotherapy applied in metastatic colorectal cancer (mCRC) does not significantly improve…”
Get full text

14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group by SIEBER, M, BREDENFELD, H, SOEKLER, M, EICH, H, MÜLLER-HERMELINK, H. K, FRANKLIN, J, PAULUS, U, WOLF, J, ENGERT, A, DIEHL, V, JOSTING, A, REINEKE, T, RUEFFER, U, KOCH, T, NAUMANN, R, BOISSEVAIN, F, KOCH, P, WORST, P

“…This multicenter pilot study assessed the feasibility and efficacy of a time-intensified bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,…”
Get full text

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group by Diehl, V, Franklin, J, Hasenclever, D, Tesch, H, Pfreundschuh, M, Lathan, B, Paulus, U, Sieber, M, Rueffer, J U, Sextro, M, Engert, A, Wolf, J, Hermann, R, Holmer, L, Stappert-Jahn, U, Winnerlein-Trump, E, Wulf, G, Krause, S, Glunz, A, von Kalle, K, Bischoff, H, Haedicke, C, Duehmke, E, Georgii, A, Loeffler, M

“…The HD9 trial aims to evaluate whether moderate dose escalation and/or acceleration of standard polychemotherapy is beneficial for advanced-stage Hodgkin's…”
Get more information

Low-Dose Radiation Is Sufficient for the Noninvolved Extended-Field Treatment in Favorable Early-Stage Hodgkin’s Disease: Long-Term Results of a Randomized Trial of Radiotherapy Alone by DÜHMKE, Eckhart, FRANKLIN, Jeremy, LATHAN, Bernd, RÜFFER, Ulrich, SIEBER, Markus, WOLF, Jürgen, ENGERT, Andreas, GEORGII, Axel, STAAR, Susanne, HERRMANN, Richard, BEYKIRCH, Maria, KIRCHNER, Hartmut, PFREUNDSCHUH, Michael, EMMINGER, Adelheid, GREIL, Richard, FRITSCH, Esther, KOCH, Peter, DROCHTERT, Angelika, BROSTEANU, Oana, HASENCLEVER, Dirk, LOEFFLER, Markus, DIEHL, Volker, SEHLEN, Susanne, WILLICH, Norman, RÜHL, Ursula, MÜLLER, Rolf-Peter, LUKAS, Peter, ATZINGER, Anton, PAULUS, Ursula

“…To show that radiotherapy (RT) dose to the noninvolved extended field (EF) can be reduced without loss of efficacy in patients with early-stage Hodgkin's…”
Get full text

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG) by Josting, Andreas, Rudolph, Christian, Mapara, Markus, Glossmann, Jan-Peter, Sieber, Markus, Kirchner, Hartmut H., Dörken, Bernd, Hossfeld, Dieter K., Kisro, Jens, Metzner, Bernd, Berdel, Wolfgang E., Diehl, Volker, Engert, Andreas

“…Purpose: Combination chemotherapy can cure patients (pts) with Hodgkin lymphoma (HD), but those with treatment failure or relapse still have a poor prognosis…”
Get full text